Desvenlafaxine
Product Images NDC 68151-5295

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Desvenlafaxine (NDC 68151-5295). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Carilion Materials Management, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 2: Impact Of Desvenlafaxine On Pharmacokinetics (pk) Of Desipramine, Midazolam, Tamoxifen And Aripiprazole (Image 01)

A pharmacokinetic interaction chart showing the effect of desvenlafaxine on various interacting drugs including desipramine, midazolam, tamoxifen, and aripiprazole at different dosages (50 mg, 100 mg, 400 mg extended-release). The chart displays fold changes in Cmax and AUC with 90% confidence intervals, along with dose adjustment recommendations relative to reference levels.*

FDA Label Image

Figure 3: Impact Of Intrinsic Factors (renal, Hepatic Impairment And Population Description) (Image 02)

A pharmacokinetic chart illustrating fold changes and 90% confidence intervals for Cmax and AUC in Desvenlafaxine use across renal and hepatic impairments and population subgroups. Recommendations on dose adjustments based on impairment severity and demographic factors are provided alongside the data.*

FDA Label Image

Figure 1: Impact Of Other Drugs On Desvenlafaxine Pharmacokinetics (pk) (Image 03)

A pharmacokinetic chart showing the fold change and 90% confidence interval for Cmax and AUC of Desvenlafaxine when co-administered with CYP3A4 inhibitor Ketoconazole. The chart indicates no dose adjustment is recommended, with changes relative to reference ranging from 0.50 to 2.00 fold.*

FDA Label Image

Desvenlafaxine Structural Formula (Image 04)

Chemical structure of desvenlafaxine monohydrate, showing its molecular components including a cyclohexanol group and a succinate moiety with a water molecule.*

FDA Label Image

Figure 4: Estimated Proportion Of Relapses Vs. Number Of Days Since Randomization (study 5) (Image 07)

A Kaplan-Meier curve showing the estimated proportion of patients with relapse over time (days from randomization). The graph compares Desvenlafaxine Extended-Release Tablets 50 mg versus placebo, with relapse percentages on the y-axis and time on the x-axis. The placebo group shows a higher relapse proportion than the Desvenlafaxine group over approximately 190 days.*

FDA Label Image

Figure 5: Estimated Proportion Of Relapses Vs. Number Of Days Since Randomization (study 6) (Image 08)

A Kaplan-Meier plot showing the estimated proportion of patients with relapse (%) over time (days from randomization) comparing Desvenlafaxine Extended-Release Tablets with placebo. The graph has two lines: a solid line for Desvenlafaxine and a dashed line for placebo, illustrating relapse rates over a period up to around 180 days.*

FDA Label Image

Label Image (Lbl681515295)

Label for Desvenlafaxine Extended-Release 50 mg tablet. Manufacturer is Mylan. The label includes lot number and expiration date fields, instructions noting prescription use only, and a barcode. The label is from Carilion Materials Management, with NDC 68151-5295.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.